CMS decision allows CED for percutaneous image guided lumbar decompression

A recent decision by CMS permits Coverage with Evidence Development status for percutaneous image guided lumbar decompression in the treatment of patients with lumbar spinal stenosis who are enrolled in such studies.
“We are very pleased with the decision of CMS to allow [Coverage with Evidence Development] CED for this very promising technology,” Earl R. Fender, president and chief executive officer of VertiFlex Inc, a minimally invasive spinal surgery technology company, stated in a company press release.
“There now exists a pathway for reimbursement for PILD [percutaneous image guided lumbar decompression] procedures … Medicare beneficiaries,” Fender, whose company specializes in their own proprietary form of PILD, stated.
The PILD option allows surgeons to remove targeted ligament, bone, and facet capsule material. PILD involves minimal disruption of the surrounding tissue and can be performed under local anesthesia.
“We appreciate CMS’ leadership in allowing Coverage with Evidence Development, and look forward to working with them to finalize a robust clinical trial protocol,” Fender stated in the release.

A recent decision by CMS permits Coverage with Evidence Development status for percutaneous image guided lumbar decompression in the treatment of patients with lumbar spinal stenosis who are enrolled in such studies.
“We are very pleased with the decision of CMS to allow [Coverage with Evidence Development] CED for this very promising technology,” Earl R. Fender, president and chief executive officer of VertiFlex Inc, a minimally invasive spinal surgery technology company, stated in a company press release.
“There now exists a pathway for reimbursement for PILD [percutaneous image guided lumbar decompression] procedures … Medicare beneficiaries,” Fender, whose company specializes in their own proprietary form of PILD, stated.
The PILD option allows surgeons to remove targeted ligament, bone, and facet capsule material. PILD involves minimal disruption of the surrounding tissue and can be performed under local anesthesia.
“We appreciate CMS’ leadership in allowing Coverage with Evidence Development, and look forward to working with them to finalize a robust clinical trial protocol,” Fender stated in the release.